Dr Morena Makhoana Appointed as the CEO of the Biovac Institute

28 May 2010

On behalf of The Biovac Institute’s Board, have pleasure in officially announcing the appointment of Dr Morena Makhoana as the new Chief Executive Officer of The Biovac Institute with effect from 1 June 2010.

The Biovac Institute remains on track in establishing a human vaccine development and manufacturing platform for Sub-Saharan Africa, whilst sourcing and supplying vaccines to the Expanded Programme on Immunisation in South Africa and beyond. At the centre of our building blocks in this establishment, is the development of relevant local skills and capacity to meet exacting demands of our business operations. Dr Makhoana has served as the Deputy Chief Executive Officer of The Biovac Institute for the past 2 years and has proven to be a strong and visionary leader capable of meeting those rigorous demands. In it is in this light that the Board has, with an unambiguous resolution, agreed to this appointment and which I am proud to announce. 

In this regard, our heartfelt gratitude goes to Mr Selwyn Kahanovitz, TBI’s current Chief Executive Officer, for his courage, drive and vision. This is further extended to the management and staff of The Biovac Institute who, during Dr Makhoana’s tenure as Deputy CEO showed their support and commitment to him, aiding him in realizing this appointment. 

We are confident that Dr Makhoana will continue to build on the solid foundation laid by Mr Kahanovitz and grow The Biovac Institute into a world class African vaccine manufacturing facility. We are sure that Dr Makhoana will bring a new spirit of aspiration to an already great institution. 

We wish Dr Makhoana great happiness and fulfilment as he assumes his new position, in which we trust he will have a long and distinguished tenure serving in his new role as CEO.